The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.
Also called NCT05532800
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 255 participants
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Registry
-
NCT05532800
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05532800. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-02-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
- Condition
- Hyperlipemia
- Intervention (Drug)
- JS002
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Record details
- Record id
cardio:ct-nct05532800- Content hash
4f208eb5029ac36c7de054a4a2c9acfbe33e77b7a6882d1e72d557b4cdf9103a